Baseline D-dimer as a predictor of immune checkpoint inhibitor efficacy in cancer

Key Points

• The research aims to determine whether baseline D-dimer levels can predict the effectiveness of immune checkpoint inhibitors in cancer treatment.
• Prospective multicenter observational study design
• Measurement of baseline D-dimer levels in patients undergoing treatment with immune checkpoint inhibitors
• Analysis of treatment outcomes in relation to D-dimer levels
• Higher baseline D-dimer levels are associated with inferior treatment outcomes in cancer patients
• D-dimer may serve as a cost-effective biomarker for patient stratification
• Further studies are needed to validate the identified cutoff thresholds for D-dimer levels